Do you want to read an article? Please log in or register.
Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis.
Rheumatoid Arthritis
Related content
Rheumatoid Arthritis
Autophagy defection in fibroblast-like synoviocytes lead to immune enhancement potential in rheumatoid arthritis.
Oncotarget.
Yang R, Zhang Y, Wang L, Hu J, Wen J, Xue L, Tang M, Liu Z, Fu J
doi: 10.18632/oncotarget.14331.
Rheumatoid Arthritis
Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes
Nat Rev Rheumatol.
Nygaard G, Firestein GS
doi: 10.1038/s41584-020-0413-5.
COMMENTED
PsoriasisRheumatoid Arthritis
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/S2468-1253(19)30362-0.
Rheumatoid Arthritis
Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
Front Immunol.
Arntz OJ, Pieters BCH, Thurlings RM, Wenink MH, van Lent PLEM, Koenders MI, van den Hoogen FHJ, van der Kraan PM, van de Loo FAJ
doi: 10.3389/fimmu.2018.02388.
OsteoarthritisRheumatoid ArthritisSystemic Lupus Erythematosus
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
Arthritis Res Ther.
Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, Veale DJ, Fearon U, Pitzalis C, Humby F, Bombardieri M, Axel A, Adams H 3rd, Chiu C, Sharp M, Alvarez J, Anderson I, Madakamutil L, Nagpal S, Guo Y
doi: 10.1186/s13075-018-1578-z.
Psoriatic ArthritisRheumatoid Arthritis
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis
Rheumatology (Oxford).
Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, Li Y, Liu J, Othman AA, Khatri A, Mansikka HT, Leszczynski P
doi: 10.1093/
Rheumatoid Arthritis
Measuring inflammatory foot disease in rheumatoid arthritis: development and validation of the Rheumatoid Arthritis Foot Disease Activity Index-5
Arthritis Care Res (Hoboken).
Hoque A, Gallagher K, McEntegart A, Porter D, Steultjens M, Woodburn J, Hendry GJ
doi: 10.1002/acr.24259.
Rheumatoid Arthritis
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Semin Arthritis Rheum.
Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium
doi: 10.1016/
Rheumatoid Arthritis
Precision Medicine with Leflunomide: Consideration of DHODH Haplotype and Plasma Teriflunomide Concentration can Substantially Modify Outcomes in Patients with Rheumatoid Arthritis
Arthritis Care Res (Hoboken).
Wiese MD, Hopkins AM, King C, Wechalekar MD, Lee A, Spargo L, Metcalf R, McWilliams L, Hill C, Cleland LG, Proudman SM
doi: 10.1002/acr.24236.